Binetrakin
- Generic Name
- Binetrakin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 207137-56-2
- Unique Ingredient Identifier
- 751635Z921
- Background
Binetrakin has been used in trials studying the treatment of HIV Infections, Sarcoma, Kaposi, Non-Hodgkin's Lymphoma (NHL), Myelodysplastic Syndrome (MDS), and Leukemia, Acute Myelogenous (AML), among others.
- Associated Conditions
- -
- Associated Therapies
- -
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
- Conditions
- Interventions
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT00923910
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 48
- Registration Number
- NCT00000769
- Locations
- 🇺🇸
UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston, Massachusetts, United States
A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00001564
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.